Icotrokinra Meets Primary Endpoint in Ulcerative Colitis Study
March 10, 2025
Topline results also show investigational targeted oral peptide icotrokinra achieved clinical remission rates up to 30.2% at Week 12 and a favorable safety profile in Phase 2b ANTHEM-UC study Johnson & Johnson